SGMO
Sangamo Therapeutics, Inc. NASDAQ Listed Apr 6, 2000$0.10
Mkt Cap $42.5M
52w Low $0.10
0.1% of range
52w High $0.77
50d MA $0.30
200d MA $0.46
P/E (TTM)
-0.3x
EV/EBITDA
-1.2x
P/B
—
Debt/Equity
-1.9x
ROE
861.6%
P/FCF
-1.2x
RSI (14)
—
ATR (14)
—
Beta
1.50
50d MA
$0.30
200d MA
$0.46
Avg Volume
7.0M
Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes; and ZFP transcription factors proteins used in increasing or decreasing gene expression. It develops SB-525, which is in Phase III AFFINE clinical trial for the treatment of hemophilia A; ST-920, a gene therapy, which is in Phase I/II STAAR clinical trials for the treatment of Fabry disease; and SAR445136, a cell therapy, which is in Phase I/II PRECIZN-1 clinical trials for the treatment of sickle cell disease. The company also develops TX200, chimeric antigen receptor for the treatment of HLA-A2 mismatched kidney transplant rejection; KITE-037, a cell therapy for the treatment of cancer; ST-501 for the treatment of tauopathies; and ST-502 for the treatment of synucleinopathies, including Parkinson's disease and neuromuscular disease. It has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Brisbane, California.
501 Canal Blvd · Richmond, CA 94005 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 30, 2026 | AMC | 0.01 | -0.11 | -1317.8% | 0.31 | -23.5% | -19.7% | -15.4% | -2.3% | -9.3% | -16.7% | — |
| Nov 6, 2025 | AMC | -0.03 | -0.11 | -266.7% | 0.46 | +0.3% | +2.5% | +11.7% | +9.1% | +2.1% | -2.5% | — |
| Aug 7, 2025 | AMC | -0.07 | -0.08 | -14.3% | 0.48 | -6.8% | -5.3% | -8.7% | +7.2% | +11.8% | +11.9% | — |
| May 12, 2025 | AMC | -0.11 | -0.14 | -27.3% | 0.75 | -37.1% | -38.4% | -41.3% | -39.7% | -37.1% | -33.2% | — |
| Mar 17, 2025 | AMC | -0.09 | -0.11 | -22.2% | 1.01 | -10.0% | -16.2% | -13.9% | -16.9% | -14.2% | -13.9% | — |
| Nov 12, 2024 | AMC | 0.01 | 0.04 | +238.2% | 2.71 | -17.0% | -10.0% | -20.7% | -24.4% | -29.9% | -27.7% | — |
| Aug 6, 2024 | AMC | -0.16 | -0.17 | -6.2% | 0.99 | -0.0% | -13.5% | -7.5% | +3.0% | +11.1% | -1.5% | — |
| May 9, 2024 | AMC | -0.22 | -0.27 | -22.7% | 0.52 | +1.3% | +7.3% | +5.3% | +8.5% | +10.8% | +16.3% | — |
| Mar 13, 2024 | AMC | -0.25 | -0.34 | -36.0% | 0.79 | +7.0% | -0.6% | -0.6% | +8.4% | -1.9% | +3.9% | — |
| Nov 1, 2023 | AMC | -0.33 | -0.34 | -3.0% | 0.59 | -7.8% | -22.1% | -22.1% | -25.3% | -28.9% | -35.7% | — |
| Aug 8, 2023 | AMC | -0.35 | -0.37 | -5.7% | 1.14 | -2.6% | -7.9% | -5.3% | -5.3% | -10.5% | -11.4% | — |
| May 8, 2023 | AMC | -0.33 | 0.12 | +136.4% | 1.27 | +0.0% | +0.8% | +0.0% | +2.4% | +3.1% | +5.5% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.40 | $0.40 | +0.0% | -2.5% | -2.2% | -5.3% | -3.3% | -7.5% |
| Nov 7 | Barclays | Downgrade | Overweight → Equal Weight | — | $0.46 | $0.46 | +0.3% | +2.5% | +11.7% | +9.1% | +2.1% | -2.5% |
| Sep 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.53 | $0.52 | -2.8% | -0.7% | +2.5% | -1.7% | -2.7% | -0.4% |
| Jun 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.43 | $0.45 | +4.7% | +18.9% | +34.7% | +29.0% | +25.2% | +25.3% |
| May 14 | Barclays | Maintains | Overweight → Overweight | — | $0.46 | $0.50 | +8.0% | -4.8% | -2.2% | +2.2% | +8.4% | +8.5% |
| Apr 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.66 | $0.60 | -8.6% | +7.7% | -4.4% | +6.4% | +10.3% | +9.4% |
| Mar 18 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $1.01 | $0.91 | -10.0% | -16.2% | -13.9% | -16.9% | -14.2% | -13.9% |
| Jan 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.16 | $1.12 | -3.4% | -2.6% | -2.6% | -2.6% | +6.0% | +6.0% |
| Jan 23 | Truist | Maintains | Buy → Buy | — | $1.15 | $1.13 | -1.7% | +3.5% | +0.9% | -1.7% | -1.7% | -1.7% |
| Jan 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.02 | $1.02 | +0.0% | +10.8% | +27.5% | +32.4% | +34.3% | +19.6% |
| Dec 31 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $2.34 | $1.07 | -54.3% | -56.4% | -51.7% | -44.4% | -42.3% | -41.5% |
| Dec 31 | Jefferies | Maintains | Buy → Buy | — | $2.34 | $1.07 | -54.3% | -56.4% | -51.7% | -44.4% | -42.3% | -41.5% |
| Dec 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.31 | $2.30 | -0.4% | +6.9% | +3.5% | +8.2% | +13.9% | +10.8% |
| Dec 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.35 | $2.72 | +15.7% | -1.7% | +5.1% | +1.7% | +6.4% | +11.9% |
| Dec 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.00 | $2.00 | +0.0% | -2.5% | -3.0% | -4.5% | +2.5% | +32.5% |
| Nov 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.44 | $2.53 | +3.7% | -11.9% | -16.0% | -22.1% | -19.7% | -20.1% |
| Nov 14 | Barclays | Maintains | Overweight → Overweight | — | $2.44 | $2.53 | +3.7% | -11.9% | -16.0% | -22.1% | -19.7% | -20.1% |
| Nov 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.74 | $1.81 | +4.0% | +24.1% | +42.0% | +61.5% | +64.9% | +55.2% |
| Oct 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.21 | $1.33 | +9.9% | +27.3% | +23.1% | +24.0% | +68.6% | +65.3% |
| Oct 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.91 | $1.23 | +34.7% | +32.5% | +68.7% | +63.2% | +64.3% | +123.4% |
| Aug 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.88 | $0.88 | +0.6% | -1.7% | -2.0% | -7.3% | -6.5% | -9.7% |
| Jul 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.70 | $0.70 | +0.0% | +11.8% | +0.7% | +24.5% | +9.7% | +41.5% |
| Jul 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.40 | $0.72 | +79.4% | +39.5% | +67.5% | +115.5% | +128.4% | +74.4% |
| May 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.57 | $0.59 | +3.9% | +2.1% | +7.2% | +14.4% | +8.2% | +5.2% |
| Mar 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.85 | $0.87 | +2.2% | -9.5% | -4.1% | +14.0% | -17.4% | -24.6% |
| Mar 14 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $0.79 | $0.84 | +7.0% | -0.6% | -0.6% | +8.4% | -1.9% | +3.9% |
| Mar 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.86 | $0.88 | +2.2% | -8.8% | -9.4% | -9.4% | -1.2% | -10.6% |
| Feb 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.57 | $0.62 | +8.5% | +40.1% | +16.7% | +31.2% | +82.8% | +140.3% |
| Feb 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.56 | $0.57 | +1.8% | -7.0% | -13.4% | -1.8% | +2.6% | +43.8% |
| Jan 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.42 | $0.44 | +5.2% | +3.9% | +9.4% | +9.3% | +6.3% | +8.8% |
| Nov 7 | Truist | Downgrade | Buy → Hold | — | $0.44 | $0.43 | -3.3% | -4.9% | -13.9% | -25.5% | -32.7% | -31.5% |
| Nov 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.46 | $0.46 | -1.1% | -4.0% | -8.7% | -17.4% | -28.5% | -35.4% |
| Nov 6 | Wells Fargo | Downgrade | Overweight → Equal Weight | — | $0.46 | $0.46 | -1.1% | -4.0% | -8.7% | -17.4% | -28.5% | -35.4% |
| Nov 3 | RBC Capital | Downgrade | Outperform → Sector Perform | — | $0.46 | $0.46 | -1.1% | +0.0% | -4.0% | -8.7% | -17.4% | -28.5% |
| Aug 15 | Truist | Maintains | Buy → Buy | — | $1.02 | $1.05 | +2.9% | -1.0% | -9.2% | -9.9% | -10.1% | -9.5% |
| Aug 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.08 | $1.06 | -1.9% | -5.6% | -6.5% | -14.2% | -14.9% | -15.1% |
| Aug 11 | Wedbush | Maintains | Outperform → Outperform | — | $1.08 | $1.06 | -1.9% | +0.0% | -5.6% | -6.5% | -14.2% | -14.9% |
| Aug 10 | Wells Fargo | Maintains | Overweight → Overweight | — | $1.05 | $1.07 | +1.9% | +2.9% | +2.9% | -2.9% | -3.8% | -11.8% |
| Aug 9 | Barclays | Maintains | Overweight → Overweight | — | $1.14 | $1.11 | -2.6% | -7.9% | -5.3% | -5.3% | -10.5% | -11.4% |
| Aug 9 | RBC Capital | Maintains | Outperform → Outperform | — | $1.14 | $1.11 | -2.6% | -7.9% | -5.3% | -5.3% | -10.5% | -11.4% |
| May 10 | Truist | Maintains | Buy → Buy | — | $1.28 | $1.28 | +0.0% | -0.8% | +1.6% | +2.3% | +4.7% | +1.6% |
| May 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.47 | $1.44 | -2.0% | +2.7% | -6.8% | -9.5% | -7.5% | -8.8% |
| Apr 28 | BofA Securities | Downgrade | Neutral → Underperform | — | $1.60 | $1.40 | -12.5% | -8.1% | -5.6% | -14.4% | -16.9% | -15.0% |
| Mar 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.96 | $2.95 | -0.3% | -3.7% | -13.9% | -15.9% | -16.9% | -22.3% |
| Feb 27 | Wedbush | Upgrade | Neutral → Outperform | — | $2.65 | $2.95 | +11.1% | +11.5% | +14.9% | +11.1% | +11.5% | +7.3% |
| Feb 23 | RBC Capital | Maintains | Outperform → Outperform | — | $2.91 | $3.14 | +7.9% | +0.3% | -8.8% | +1.7% | +4.8% | +1.4% |
| Jan 4 | Wells Fargo | Maintains | Overweight → Overweight | — | $3.14 | $3.15 | +0.3% | +5.9% | +7.6% | +5.4% | +0.3% | +7.3% |
| Nov 7 | Wells Fargo | Maintains | Overweight → Overweight | — | $3.62 | $3.65 | +0.8% | -6.4% | -4.7% | -7.7% | +10.2% | +11.3% |
| Apr 5 | Truist | Maintains | Buy → Buy | — | $6.21 | $6.17 | -0.6% | -1.0% | +0.0% | -5.6% | -8.4% | -13.0% |
| Jun 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.82 | $8.82 | +0.0% | +3.9% | +9.1% | +3.4% | +3.9% | -1.0% |
No insider trades available.
8-K
Unknown — 8-K Filing
Sangamo's positive Phase 3 STAAR data showing kidney function stabilization in Fabry disease patients strengthens its lead pipeline asset and path to potential FDA approval, validating its gene-editing therapeutic approach.
Mar 30
8-K · 1.01
!! High
Sangamo Therapeutics, Inc. -- 8-K 1.01: Material Agreement
Sangamo Therapeutics secured a $25 million agreement with Cantor Fitzgerald, likely providing capital or financial services to support the company's gene therapy development pipeline.
Feb 4
8-K
Sangamo Therapeutics, Inc. -- 8-K Filing
Sangamo Therapeutics' CFO Prathyusha Duraibabu departed, with VP Nikunj Jain assuming interim CFO duties, signaling potential leadership transition and possible strategic changes ahead.
Feb 3
8-K
Sangamo Therapeutics, Inc. -- 8-K Filing
Sangamo Therapeutics presented Phase 1/2 STAAR study results for isaralgagene civaparvovec in Fabry disease patients, showing a single infusion followed by 52-week monitoring, supporting potential clinical advancement for this gene therapy.
Feb 3
Data updated apr 27, 2026 1:00am
· Source: massive.com